The deal will give Novartis SNV4818, which is designed to more precisely target PIK3CA-mutated cancer cells and may avoid the toxicities seen with Piqray, the company hopes.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs ...
Clinical Trials Arena on MSN
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results